SMARCA4 and hematopoietic and lymphoid cell neoplasm: Across a wide variety of hematological and non-hematological cancers, mutations in SMARCA4 are usually missense and heterozygous, and many of them have been proven to be dominant negative in at least some cellular contexts [118, 119].